中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.021 seconds)

    Ｔ―타입 칼슘채널을 억제하여 불안 장애를 치료하는 방법
    2.
    发明授权
    Ｔ―타입 칼슘채널을 억제하여 불안 장애를 치료하는 방법 失效
    一种调节T型钙通道治疗焦虑症的方法

    公开(公告)号：KR100958291B1

    公开(公告)日：2010-05-19

    申请号：KR1020080032799

    申请日：2008-04-08

    Applicant: 한국과학기술연구원

    Inventor： 신희섭 ,  이석찬 ,  김희수

    IPC: A61K31/41 ,  A61K31/675 ,  A61P25/22

    CPC classification number: A61K31/41

    Abstract: 본 발명은 Ｔ-타입 칼슘 채널 억제제를 함유하는 불안장애 예방 및 치료용 조성물, 및 상기 조성물을 시상의 등쪽 내측 핵(mediodorsal thalamus, MD)에 투여하여 불안장애를 예방 및 치료하는 방법에 관한 것으로, Ｔ-타입 칼슘 채널 억제제인 미베프라딜(mibefradil)을 MD에서 많이 발현되는 포스포리파제β4(Phospholipaseβ4, PLCβ4)의 유전자가 녹-아웃(knock-out)된 마우스의 MD에 투여하면 상기 마우스에서 저하되었던 기억 소멸 능력이 정상적으로 돌아오며, 미베프라딜 및 에포니디핀(efonidipine)을 정상 마우스의 MD에 투여하면 상기 마우스에서 공포 기억이 빨리 소멸하고 상기 소멸한 기억의 회상 능력이 감소하는 것을 확인함으로써, Ｔ-타입 칼슘 채널 억제제는 불안장애 예방 및 치료에 유용하게 이용될 수 있다.
    Ｔ-타입 칼슘 채널 억제제, 미베프라딜, 에포니디핀, 불안장애

    Ｔ―타입 칼슘채널을 억제하여 불안 장애를 치료하는 방법
    3.
    发明公开
    Ｔ―타입 칼슘채널을 억제하여 불안 장애를 치료하는 방법 失效
    通过调节T型钙通道治疗放射性疾病的方法

    公开(公告)号：KR1020090081307A

    公开(公告)日：2009-07-28

    申请号：KR1020080032799

    申请日：2008-04-08

    Applicant: 한국과학기술연구원

    Inventor： 신희섭 ,  이석찬 ,  김희수

    IPC: A61K31/41 ,  A61K31/675 ,  A61P25/22

    CPC classification number: A61K31/41

    Abstract: A method for treating anxiety disorder by suppressing T-type calcium channel is provided to quickly eliminate phobia memory by administering a composition inside thalamus and reduce reminiscence to phobia memory. A method for treating anxiety disorder by suppressing T-type calcium channel comprises a step of administering in pharmaceutically active amount of inhibitor for T-type calcium channel to subject. The anxiety disorder is phobic disorder, generalized anxiety disorder, obsessive compulsive disorder, post-traumatic stress disorder, somatoform disorder, dissociative disorder and factitious disorder.

    Abstract translation: 提供通过抑制T型钙通道治疗焦虑症的方法，通过在丘脑内施用组合物并减少对恐惧记忆的回忆以快速消除恐惧症记忆。 通过抑制T型钙通道来治疗焦虑症的方法包括以药学活性量向受试者施用T型钙通道抑制剂的步骤。 焦虑症是恐怖症，广泛性焦虑症，强迫症，创伤后应激障碍，躯体形式障碍，解离障碍和情感障碍。

    불안장애 치료제 효과 검증 모델 동물로서의 ＰＬＣβ４돌연변이 생쥐
    5.
    发明公开
    불안장애 치료제 효과 검증 모델 동물로서의 ＰＬＣβ４돌연변이 생쥐 失效
    PLCbeta4 MUTANT MICE作为测试麻醉药物的模型

    公开(公告)号：KR1020090081232A

    公开(公告)日：2009-07-28

    申请号：KR1020080007202

    申请日：2008-01-23

    Applicant: 한국과학기술연구원

    Inventor： 신희섭 ,  이석찬 ,  김희수 ,  최석우 ,  홍인기

    IPC: A01K67/027

    CPC classification number: A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0356

    Abstract: Provided are a method or a use of using a PLC beta4 knock-out animal as an anxiety disorder animal model, and a method of screening anxiety disorder-preventing and treating agents using the animal. A method of using a PLC beta4 knock-out animal as an anxiety disorder animal model comprises using an animal in which a PLC beta4(phospholipase beta4) gene representing a lack in the memory disappearing capability is knocked-out as an anxiety disorder animal model. A use of using a PLC beta4 knock-out animal as an anxiety disorder animal model comprises using an animal in which a PLC beta4(phospholipase beta4) gene representing a lack in the memory disappearing capability is knocked-out as an anxiety disorder animal model. A method of screening anxiety disorder-preventing and treating agents comprises the steps of: injecting candidate materials of the anxiety disorder-preventing and treating agents into an animal in which a PLC beta4(phospholipase beta4) gene is knocked-out; testing the memory disappearing capability of the animal; and sorting the candidate material that has attentively recovered the memory disappearing capability as compared with a control group into which the candidate materials have not been injected.

    Abstract translation: 提供了使用PLC beta4敲除动物作为焦虑障碍动物模型的方法或使用，以及使用该动物筛选焦虑障碍预防和治疗剂的方法。 使用PLCβ4敲除动物作为焦虑障碍动物模型的方法包括使用其中表示缺乏记忆消失能力的PLCβ4（磷脂酶β4）基因作为焦虑障碍动物模型被敲除的动物。 使用PLCβ4敲除动物作为焦虑症动物模型包括使用其中表示缺乏记忆消失能力的PLCβ4（磷脂酶β4）基因作为焦虑障碍动物模型被敲除的动物。 筛选焦虑障碍预防和治疗剂的方法包括以下步骤：将焦虑障碍预防和治疗剂的候选材料注射到其中敲除了PLCβ4（磷脂酶β4）基因的动物中; 测试动物的记忆消失能力; 并且与候选材料未被注入的对照组相比，对已经认真地恢复记忆消失能力的候选材料进行排序。

    정신분열증 치료제 효과 검증 모델로서의ＰＬＣβ１돌연변이 생쥐
    6.
    发明授权
    정신분열증 치료제 효과 검증 모델로서의ＰＬＣβ１돌연변이 생쥐 失效
    PLCBETA; 1个MUTANT MICE作为测试SCHIZOPHRENIA药物的模型

    公开(公告)号：KR100795461B1

    公开(公告)日：2008-01-16

    申请号：KR1020060093541

    申请日：2006-09-26

    Applicant: 한국과학기술연구원

    Inventor： 고혜영 ,  신희섭 ,  김대수 ,  이석찬

    IPC: A61K48/00 ,  A61P25/18

    CPC classification number: A61K49/0008

    Abstract: A mutant animal model showing endophenotypes related to schizophrenia is provided to test and screen novel drugs for prevention and treatment of schizophrenia, so that the convenience and rapidness of drug testing and screening are improved. A method for screening a drug for prevention and treatment of schizophrenia comprises the steps of: (1) injecting candidate drugs for schizophrenia into a mutant animal model showing endophenotypes related to schizophrenia due to knock-out of a phospholipase beta1 gene; (2) measuring at least one endophenotype of schizophrenia selected from increase of locomotor activity, PPI(prepulse inhibition) damage of startle response, lack of barbering and nesting activities, socially inferior trait, study damage in Morris water maze test and deficient type-II theta rhythm associated with working memory; and (3) comparing the measured schizophrenia endophenotype with that of a control group which is not injected by the candidate drugs and selecting candidate drug for significantly reducing the schizophrenia endophenotype, wherein the animal model is a mice PLCbeta1(phospholipase Cbeta1).

    Abstract translation: 提供显示与精神分裂症相关的内在表型的突变动物模型，用于检测和筛选用于预防和治疗精神分裂症的新药，从而提高药物检测和筛选的方便性和快速性。 筛选用于预防和治疗精神分裂症的药物的方法包括以下步骤：（1）将用于精神分裂症的候选药物注射到显示由于磷脂酶β1基因敲除引起的与精神分裂症有关的内在表型的突变动物模型中; （2）测量精神分裂症的至少一种，选自运动活动增加，惊厥反应的PPI（前脉冲抑制）损伤，缺乏理发和嵌套活动，社会劣势性状，Morris水迷宫试验和缺陷型II的研究损伤 与工作记忆相关的θ节奏; 和（3）比较测定的精神分裂症内表型与不被候选药物注射的对照组的精神分裂症表型，并选择用于显着降低精神分裂症内表型的候选药物，其中动物模型为小鼠PLCbeta1（磷脂酶Cbeta1）。

Patent Agency Ranking